Realizing the promise of precision medicine in oncology

We’re delighted to announce the launch of our TruSight™ Oncology Comprehensive (EU), our newest CE-marked IVD test for Comprehensive Genomic Profiling (CGP). Pathologists and Oncologists can now benefit from end-to-end solution that:

• Detects majority of approved and emerging therapy biomarkers across multiple solid tumour types, including those in ESMO recommendations, EMA drug labels and local clinical trials
• Maximizes ability to find actionable alterations, that can inform therapy regimens for cancer patients
• Consolidates multiple individual iterative tests into a single CGP workflow, saving biopsy sample and precious time, so oncologists can make timely decisions for their patients
• Has been validated by Illumina, is kitted and IVD labelled, so your organization can internalize the test and offer through your institutions